Viruses (Jul 2022)

Performance of Cardiotropic rAAV Vectors Is Dependent on Production Method

  • Renuka Rao,
  • Melad Farraha,
  • Grant J. Logan,
  • Sindhu Igoor,
  • Cindy Y. Kok,
  • James J. H. Chong,
  • Ian E. Alexander,
  • Eddy Kizana

DOI
https://doi.org/10.3390/v14081623
Journal volume & issue
Vol. 14, no. 8
p. 1623

Abstract

Read online

Gene therapy is making significant impact on a modest, yet growing, number of human diseases. Justifiably, the preferred viral vector for clinical use is that based on recombinant adeno-associated virus (rAAV). There is a need to scale up rAAV vector production with the transition from pre-clinical models to human application. Standard production methods based on the adherent cell type (HEK293) are limited in scalability and other methods, such as those based on the baculovirus and non-adherent insect cell (Sf9) system, have been pursued as an alternative to increase rAAV production. In this study, we compare these two production methods for cardiotropic rAAVs. Transduction efficiency for both production methods was assessed in primary cardiomyocytes, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), and in mice following systemic delivery. We found that the rAAV produced by the traditional HEK293 method out-performed vector produced using the baculovirus/Sf9 system in vitro and in vivo. This finding provides a potential caveat for vector function when using the baculovirus/Sf9 production system and underscores the need for thorough assessment of vector performance when using diverse rAAV production methods.

Keywords